Summary
Cisplatin was given intravenously to 35 evaluable patients with unresectable malignant mesothelioma on Southwest Oncology Group (SWOG) Study 8418. Five patients (14.3%) achieved partial response with median response duration of six months (range 2–12 months); eleven patients (31.4%) had stable disease of median duration of 5.5. months (range 2–21 months). Median survival for all patients was 7.5 months, 9 months for responders. Toxicity was as expected except that 12 patients (34.2%) discontinued cisplatin because of side effects. Cisplatin has moderate activity in mesothelioma and further studies with platinum analogues should be pursued.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Zidar BL, Pugh RP, Schiffer LM, Raju RN, Vaidya KA, Bloom RL, Horne D, Baker LH: Treatment of six cases of mesothelioma with doxorubicin and cisplatinum. Cancer 52:1788–1791, 1983
Samson MK, Wasser LP, Borden EC, Wanebo HJ, Creech RH, Phillips M, Baker LH: Randomized comparison of cyclophosphamide, imidazole carboxamide, and adriamycin versus cyclophosphamide and adriamycin in patients with advanced stage malignant mesothelioma: A sarcoma intergroup study. J Clin Oncol 5:86–91, 1987
Mintzer DM, Kelsen D, Frimmer D, Heelan R, Gralla R: Phase II Trial of high-dose cisplatinum in patients with malignant mesothelioma. Cancer Treat Rep 69:711–712, 1985
Markman M, Cleary S, Pfeifle C, Howell SB: Cisplatinum administration by the intracavitary route as treatment for malignant mesothelioma. Cancer 58(1):18–21, 1986
Pfeifle CE, Howell SB, Markman M: Intracavitary cisplatinum chemotherapy for mesothelioma. Cancer Treat Rep 69(2):205–207, 1985
Aisner J, Sigman LM: The role of chemotherapy in the treatment of malignant mesothelioma. In: Antman K, Aisner J (ed) Asbestos-Related Malignancy. Grune and Stratton, Inc. 1987. pp 385–401.
Chahinian AP, Antman K, Aisner J, Propert K, Modeas C, Ellison RR, Stoll DB, Green M: Cisplatin with adriamycin or mitomycin for malignant mesothelioma: A randomized Phase II Trial (Abstr). Proc Am Soc Clin Oncol 6:183(#721), 1987
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Zidar, B.L., Green, S., Pierce, H.I. et al. A phase II evaluation of cisplatin in unresectable diffuse malignant mesothelioma: A Southwest Oncology Group Study. Invest New Drugs 6, 223–226 (1988). https://doi.org/10.1007/BF00175403
Issue Date:
DOI: https://doi.org/10.1007/BF00175403